Teva and MODAG Announce Global Exclusive Licensing Agreement to Develop Anle138b, a Disease-Modifying Aggregation Inhibitor for Neurodegenerative Disorders

Oct. 27, 2021 /BioonBIOON/ -- Teva Pharmaceutical Industries (Teva) and MODAG GmbH recently jointly announced that they have entered into a strategic partnership for the global exclusive licensing and development of MODAG GmbH's lead compound anle 138 and related compound sery433.anle138b targets pathological α-synuclein (α-syn) oligomers and is currently being evaluated for its potential disease-modifying effects in patients with neurodegenerative diseases.Subject to the terms of the agreement and regulatory approvals, Teva will be granted an exclusive worldwide license to develop, manufacture, and commercialize anle138b and sery433.

Based on early clinical studies, the two parties will jointly develop these compounds for the treatment of multiple system atrophy (MSA) and Parkinson's disease (PD) indications, and will consider exploring additional indications based on clinical results.It is currently believed that the pathological hallmark of MSA lies in the accumulation of a glial cell substance known as α-synuclein (α-syn), which causes pathological changes. The pathogenesis of PD also involves the excessive accumulation of α-synuclein. Therefore, these two diseases may share a certain connection.

anle138b is a novel, oral, brain-penetrant protein oligomer modulator and aggregation inhibitor., was discovered during high-throughput screening for small-molecule inhibitors of α-synuclein (α-syn) and prion protein (PrP(Sc)) oligomers.anle138b inhibits the formation of pathological aggregates of prion protein (PrP(Sc)) and α-synuclein (α-syn), demonstrating good oral bioavailability, blood-brain barrier permeability, and no detectable toxicity.

ANLE138b Chemical Structure (Image source: selleck.cn)

Currently, the compound is being developed for the treatment of the rapidly progressive synucleinopathies multiple system atrophy (MSA) and Parkinson's disease (PD). It also holds potential for application in other synucleinopathies, such as dementia with Lewy bodies (DLB).ANLE138b demonstrated a ... in neurodegenerative diseases (such as prion,Parkinson's diseaseetc.) as a novel therapy for disease-modifying treatment.

A Phase 1 study evaluating anle138b in healthy volunteers, completed in July 2020 (NCT04208152), demonstrated that anle138b exhibited a favorable benefit-risk profile at all dose levels, whilePlasma concentrations exceed those required for full therapeutic efficacy in animal models.. Anle138b was initially developed in patients with MSA and PD, with potential applications in other neurodegenerative diseases, such as Alzheimer's disease (AD). A Phase 1b trial (NCT04685265) is currently underwayClinical Trial, to evaluate the safety and efficacy of the compound in patients with PD.

Hafrun Fridriksdottir, Executive Vice President of Global R&D at Teva, stated: “Teva has a strong foundation of expertise in neuroscience, neurology, and psychiatry. This licensing and collaboration agreement adds a promising new compound to our early-stage pipeline, with the potential to offer a new option for patients with multiple system atrophy as well as Parkinson’s disease. We are excited to partner with the MODAG team and look forward to future development and to exploring additional indications for these two compounds under the collaboration.”

Original Source:Teva and MODAG Announce Licensing Collaboration for Neurodegenerative Disease Drug Candidate